SONX
Sonendo, Inc.0.2000
-0.0727-26.7%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
85.48KP/E (TTM)
-Basic EPS (TTM)
-70.63Dividend Yield
0%Recent Filings
10-K
FY2024 results
Sonendo's FY2024 revenue fell 8% y/y to $31.7M from continuing operations, reflecting 16% lower PI volume and softer console pricing, yet gross margins leaped to 37% from 13% via manufacturing efficiencies and legacy product phaseouts. Q4 trends unavailable in the 10-K, but annual operating loss narrowed 50% to $29.4M on 36% opex cuts including headcount reductions across sales, G&A, and R&D. Cash burned $24.7M in operations, ending at $11.6M with $15.1M debt; divestiture of software segment yielded $14.2M net proceeds and $5.7M gain. Debt covenants waived through 2026 pending $8M equity raise by March 2025. Delisting to OTC Pink and Form 15 filing curb disclosures. Supply chain disruptions threaten quarterly PI momentum.
8-K
Credit amendment defers payments
Sonendo entered Amendment No. 4 to its credit agreement on February 28, 2025, deferring the February amortization payment to March 31 and waiving payments through September 30, 2025, if it raises $8M via equity by March 31. Further waivers to March 2026 hinge on a $5M subsequent financing by September 30, with mandatory prepayments above $10M. Waived 2024 going-concern audit qualification. Relief buys runway, but ties to capital raises.
8-K
Q3 loss shrinks 60%
8-K
Sonendo loses Biolase auction
10-Q
Q3 FY2024 results
Sonendo's Q3 revenue from continuing operations held steady at $8.0M, down 2% y/y yet with gross margin leaping to 41% from 11% on lower PI manufacturing costs and no repeat of prior impairments. Operating loss narrowed to $6.8M from $16.6M as selling/marketing and G&A expenses fell 48% and 37%, respectively, via headcount cuts. Cash plus short-term investments stood at $17.3M against $17.8M term loan principal (monthly amortization through 2026, min cash covenant $3.0M); sold software unit March 2024 for $16.0M. EPS reconciles precisely to 478K diluted shares. Expenses slashed sharply.
DXCM
DexCom, Inc.
66.37+0.64
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
NYXH
Nyxoah SA
4.80-0.03
PHG
Koninklijke Philips N.V. NY Reg
26.53+0.07
PROF
Profound Medical Corp.
7.55-0.14
SENS
Senseonics Holdings, Inc.
6.62-0.17
SNWV
SANUWAVE Health, Inc.
31.46-0.18
SONO
Sonos, Inc.
18.24-0.09
VVOS
Vivos Therapeutics, Inc.
2.02+0.00
XRAY
DENTSPLY SIRONA Inc.
11.37-0.03